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INTRODUCTION
Although autologous blood progenitor/stem cell (BSC)
transplantation has been used in the treatment of breast
cancer, limited information is available regarding factors
inﬂuencing collection of adequate numbers of stem and pro-
genitor cells from these patients. Prior treatment with radia-
tion and chemotherapy is known to be associated with
lower numbers of progenitors in mobilized autologous
BSC collections [1,2]. Mice that have received radiation to
various parts of their bodies exhibit markedly inhibited
mobilization regardless of the area irradiated [3]. Previous
radiotherapy and chemotherapy and an older age have had
adverse effects on the efﬁciency of collection of mobilized
CD34+ cells, whereas the type of underlying malignancy
and bone marrow infiltration by malignant cells have not
had adverse effects [4].
Steady-state (ie, nonmobilized) blood stem cell collec-
tions were performed at some centers prior to 1991 [5].
Subsequently, hematopoietic cytokines (granulocyte
colony-stimulating factor or granulocyte-macrophage
colony-stimulating factor), sometimes in association with
myelotoxic chemotherapy, have been employed to produce
mobilization. Differences between collection characteris-
tics of mobilized and nonmobilized cells and their relation-
ship to bone marrow metastasis of autologous donors are
unknown. The purpose of this study was to examine the
relationship of prior therapy, mobilization, marrow metas-
tases, and BSC collection among women with breast
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ABSTRACT
This study was designed to examine the relationship of prior therapy, bone marrow metastases, mobilization, and
blood progenitor/stem cell (BSC) collection in breast cancer patients. Cells were collected from 19 breast cancer
patients during steady state (nonmobilized group) and from 69 breast cancer patients after cytokine administration
(mobilized group). Characteristics of the patients were compared with the cells obtained. A significant inverse asso-
ciation was found between the number of chemotherapy regimens the patients had received prior to BSC collection
and the mononuclear cell (MNC) count of the product per liter of blood processed (LBP) with apheresis (P = .0006)
and the granulocyte monocyte/macrophage colony-forming cell (GM-CFC) numbers per LBP (P = .0002). This
association was evident in both mobilized and nonmobilized patients. Similar results were seen in those 25 patients
who had received prior radiation therapy (MNC/LBP, P = .0003; GM-CFC/LBP, P = .0004). Patients in both the
mobilized and nonmobilized groups with marrow metastases at the time of collection also had significantly lower
levels of MNC/LBP (P = .0039) and GM-CFC/LBP (P = .0001) than did those without marrow metastases. The
findings suggest that prior administration of radiation therapy and/or chemotherapy and the presence of marrow
metastases all negatively impacted the collection of mobilized and nonmobilized progenitor cells from breast cancer
patients. The mechanisms of this impact are not understood.
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Blood stem cells were collected from 88 stage II to IV
breast cancer patients between 1987 and 1998. Eighteen of
these patients had cells collected prior to April 1991 during
steady state (nonmobilized group). The remainder had cells
collected following cytokine administration (mobilized
group). Histopathological analysis of bilateral marrow core
biopsy specimens and aspirates was performed prior to cell
collection to determine the adequacy of hematopoiesis and to
detect the presence of tumor. The following data were deter-
mined retrospectively from medical records: the total volume
of blood processed by the apheresis machine to collect the
product, the total mononuclear cell (MNC) count per kilo-
gram of body weight in the graft product and per liter of
blood processed (LBP), the total number of granulocyte-
macrophage colony-forming cells (GM-CFC) per kilogram
of body weight in the graft product and per LBP, whether or
not prior radiotherapy had been given, the number of prior
chemotherapy regimens received (a regimen was deﬁned as a
combination of speciﬁc cytotoxic agents administered in regu-
lar cycles and could include adjuvant regimens such as 5 ﬂuor-
ouracil, methotrexate, and cyclophosphamide), and the num-
ber of months myelotoxic chemotherapy had been given prior
to collection. This study was based on those 88 consecutive
patients with complete MNC and GM-CFC data whose mar-
row biopsy specimens had been evaluated for marrow metas-
tases using the immunohistochemical, immunocytochemical,
and/or histopathologic methods described below. Because
CD34+ cell counts were available only for the mobilized
group, the analysis was focused on MNC counts and GM-
CFC numbers. Data are presented separately for all patients
and for patients undergoing cytokine mobilization.
Apheresis Procedures
Sequential mobilization regimens employed daily
administration of granulocyte-macrophage colony-stimulating
factor (GM-CSF) at 125 µg/m2 and then at 250 µg/m2, fol-
lowed later by administration of G-CSF 10 µg/kg subcuta-
neously, with collections using the Cobe Spectra (Gambro
BCT, Lakewood, CO) beginning on the fifth day of
cytokine administration. Multiple apheresis procedures to
collect a target MNC dose of 6.5 × 108/kg were required for
the nonmobilized group. The target for mobilized auto-
grafts was also 6.5 × 108 MNC/kg plus 2.5 × 104 GM-CFC
up to 1994 and subsequently at least 1.1 × 106 CD34+
cells/kg. All patients participated in Institutional Review
Board–approved stem cell collection studies, and each
patient provided written informed consent for the collec-
tions and the analysis of their collections.
Hematopoietic Colony Assays
The numbers of GM-CFC in the collections were
determined using a previously described culture technique
[6]. Briefly, 3 × 105 MNCs that had been separated from
the harvest were plated in 35-mm Petri dishes containing
Iscove’s modified Dulbecco’s medium, 20% fetal bovine
serum, 50 µM 2-mercaptoethanol, 100 µg/mL strepto-
mycin, 100 U/mL penicillin, and 0.3% agar supplemented
with 200 U/mL interleukin-3, 200 U/mL GM-CSF, and
200 U/mL G-CSF. Cultures were incubated at 37°C in a
fully humidiﬁed atmosphere of 5% CO2 in air for 14 days.
Aggregates greater than 50 cells were counted as colonies.
Bone Marrow Metastases and Micrometastases
Bilateral core biopsy specimens and aspirates obtained
just prior to cell collection were examined histopathologi-
cally for the presence of tumor cells. In addition, sections of
cores were stained immunohistochemically for cytokeratins
using the MAK 6 antibody cocktail (Zymed, South San
Francisco, CA). Patients with morphological or immunohis-
tochemical evidence of tumor cells in their marrow were
characterized as histologically positive for bone marrow
metastasis. In addition, cytospin preparations were prepared
from marrow aspirates and stained immunocytochemically
for cytokeratins using the MAK 6 and Cam 5.2 (Becton
Dickinson, San Jose, CA) antibodies as described previously
[7]. Cells containing these cytokeratins were identified by
indirectly linking the anticytokeratin antibodies to glucose
oxidase, which was used as the indicator enzyme. Nitroblue
tetrazolium, which produces a purple-blue precipitate color
when reduced, was used as the substrate. Criteria for a posi-
tive result included immunoreactivity of at least 70% in the
cytoplasm and morphology consistent with that of tumor
cells. The characteristic cytoplasmic membrane staining
was observed using a light microscope. Patients with
histopathologic, immunohistochemical, or immunocyto-
chemical evidence of tumor-positive cells in bone marrow
were designated as bone marrow positive.
Data Analysis
The Kruskal-Wallis test was used to test the relationship
between product characteristics and prior chemotherapy.
The Wilcoxon test was used to test the relationship between
product characteristics and prior radiation therapy, mobi-
lization, and the presence of marrow metastases. Fisher’s
exact test was used to test the relationship between prior
chemotherapy and the presence of marrow metastases.
RESULTS
Patient Characteristics
The median age of the patients in this study was 42 years
(range, 30-62 years). Fifty-one (58%) of the 88 patients had
received 1 prior chemotherapy regimen; 28 (32%) had
received 2 prior regimens; 8 (9%) had received 3 prior regi-
mens; and 1 patient had received 5 prior regimens. The
median number of months these patients had received cyto-
toxic chemotherapy was 5 (range, 2-27 months). Twenty-ﬁve
patients (28%) had received prior radiation therapy. Twenty-
three (26%) of the 88 patients had immunocytochemically
detectable tumor cells in their bone marrow at the time of
blood stem cell collection.
Association of Prior Treatment and Collection
Characteristics
No signiﬁcant association was found between the num-
ber of prior chemotherapy regimens and the MNC count/kg
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patient wt in the graft product (P = .36), but a significant
inverse association between the number of prior chemo-
therapy regimens and MNC count/LBP (P = .0006) was
observed in all patients and in cytokine-mobilized patients.
A significant inverse association was also found for both
the number of GM-CFC progenitors/kg (P = .0003) and
GM-CFC numbers per LBP (P = .0002) in both groups. A
dose-response relationship was apparent, with more heavily
pretreated patients having lower counts (Table 1). Similar
results were found for patients with prior radiation therapy
(Table 2). The equivalence of these results for all patients, as
well as the mobilized patient cohort alone, demonstrated that
these effects were not a consequence of the mobilizing regimen.
Association of Mobilization and Collection
Characteristics
The mobilized group had signiﬁcantly higher levels of
MNC/kg (P = .0046), MNC/LBP (P = .0007), GM-CFC/kg
(P = .0001), and GM-CFC/LBP (P = .0001). The increase in
GM-CFC numbers was approximately 10-fold, and more
modest increases in MNC counts were found (data not
shown).
Association of Marrow Metastases and Collection
Characteristics
All patients whose bone marrow contained detectable
tumor cells at the time of blood stem cell collection had col-
lections that contained significantly lower levels of MNC,
with a median of 7.2 × 108/kg (range, 6.0-23.0 × 108/kg) ver-
sus 9.2 × 108/kg (range, 3.4-25.7 × 108/kg) for 65 marrow-
negative patients (P = .0063). Similarly, bone marrow–positive
patients compared to bone marrow–negative patients had a
median MNC of 8.9 × 108/LBP (range, 4.1-18.4 × 108/LBP)
versus 11.5 × 108/LBP (range, 3.8-25.1 × 108/LBP) (P =
.0039), GM-CFC of 1.1 × 104/kg (range, 0.1-58.1 × 104/kg)
versus 8.4 × 104/kg (range, 0.1-370.0 × 104/kg) (P = .0001),
and GM-CFC of 1.1 × 104/LBP (range, 0.1-93.5 ×
104/LBP) versus 10.1 × 104/LBP (range, 0.3-611.7 ×
104/LBP) (P = .0001). Although the number of GM-CFC
expressed both as 104/kg body wt and 104/LBP was signiﬁ-
cantly higher for the mobilized than for the nonmobilized
group, bone marrow tumor cell positivity was associated
with lower MNC counts (P = .029) and GM-CFC levels in
the collections of both groups, indicating that marrow posi-
tivity decreased collection efficiency, independent of
cytokine administration.
Association of Marrow Metastases and Prior
Chemotherapy
The relationship of prior chemotherapy and the detec-
tion of tumor cells in the marrow was examined separately
for the mobilized and nonmobilized groups. No signiﬁcant
relationship was found in the nonmobilized group between
the number of prior chemotherapy regimens and bone mar-
row positivity. The relationship between the number of
prior chemotherapy regimens and bone marrow metastases
Table 1. Cell Composition of Graft Products and Number of Prior Chemotherapy Regimens Received
No. of MNC × 108/LBP, No. of GM-CFC × 104/kg, No. of GM-CFC × 104/LBP,
No. of Prior Regimens No. of Patients Median (Range) Median (Range) Median (Range)
1
All 51 13.2 (2.8-25.1) 10.4 (0.4-370.0) 14.0 (0.6-611.7)
Mobilized only 45 14.2 (2.8-25.1) 13.8 (2.2-370.0) 28.4 (1.0-611.7)
2
All 28 9.6 (4.1-15.0) 3.8 (0.2-32.8) 2.5 (0.1-13.6)
Mobilized only 19 10.8 (4.1-15.0) 5.3 (1.1-32.8) 6.0 (0.5-66.0)
>2
All 9 8.9 (4.1-12.7) 2.5 (0.1-13.6) 2.2 (0.1-16.5)
Mobilized only 5 9.8 (4.1-12.7) 3.1 (2.5-13.6) 3.5 (2.2-16.5)
Significance levels
All P = .0006 P = .0003 P = .0002
Mobilized only P = .022 P < .01 P = .015
Table 2. Cell Composition of Graft Products and Prior Radiation Therapy
No. of MNC × 108/LBP, No. of GM-CFC × 104/kg, No. of GM-CFC × 104/LBP,
Prior Radiation No. of Patients Median (Range) Median (Range) Median (Range)
Yes
All 25 8.4 (4.1-15.2) 3.0 (0.1-14.5) 2.5 (0.1-25.8)
Mobilized only 17 8.7 (4.1-15.2) 5.0 (1.1-14.6) 4.8 (0.5-25.8)
No
All 63 11.5 (3.8-25.1) 8.5 (0.1-370.0) 10.1 (0.2-611.7)
Mobilized only 52 12.7 (3.8-75.1) 11.5 (2.2-370.0) 13.6 (1.1-611.7)
Significance levels
All P = .0003 P = .0013 P = .0004
Mobilized only P < .01 P ≤ .01 P < .001
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in the mobilized group was suggestive of an increased tumor
cell positivity in the marrow in patients receiving more
courses of chemotherapy, but this effect did not attain statis-
tical signiﬁcance (P = .069).
DISCUSSION
In this retrospective analysis, a statistically significant
inverse association was found between the number of prior
chemotherapy regimens patients had received, prior adminis-
tration of radiation therapy, and the presence of bone marrow
metastasis and the numbers of MNC/LBP and GM-CFC/
LBP harvested from both breast cancer patients undergoing
cytokine-mobilized and those undergoing nonmobilized
blood stem cell collection. The negative effect of prior
chemotherapy and radiation therapy on blood stem cell col-
lections from breast cancer patients has been noted previously
[8]. Also, in patients with non-Hodgkin’s and Hodgkin’s lym-
phoma, Haas et al. [9] noted that prior radiation therapy
inhibited stem/progenitor cell collection. The assumption
was that these prior therapies had damaged the stem cell
compartment, thereby reducing stem cell numbers and/or
preventing mobilization of large numbers to the circulation in
response to cytokines, although other mechanisms might also
have been operative. The sites receiving radiation therapy
were not determined, but for this group of patients, it is likely
that the chest wall and axilla predominated. Consequently, it
is unlikely that the iliac crest bone marrow biopsy sites of
these patients were irradiated. Concurrent administration of
radiation and mobilizing cytokines to mice inhibits mobiliza-
tion [3]. Because the effect was independent of the body area
irradiated, a circulating factor was suspected to be involved.
Injection of plasma from part-body irradiated mice into naive
mice prior to injecting mobilizing cytokines also inhibited
mobilization [3]. Preliminary studies have suggested this
plasma from part-body irradiated mice contained elevated
levels of transforming growth factor-β (TGF-β) [10].
Plasma from poorly mobilizing patients and from
healthy donors of blood stem cells for allogeneic transplan-
tation also inhibited mobilization when injected into naive
mice prior to mobilization attempts [11]. Therefore, along
with stem cell damage, patients who received prior radiation
therapy and/or chemotherapy may have a circulating
inhibitor of stem cell mobilization, which could decrease the
efﬁciency of stem cell collection both in nonmobilized and
in cytokine-mobilized patients as observed in this study. The
nature of this inhibitor is uncertain, but breast cancer
patients have been shown to have higher systemic levels of
TGF-β that are similar to levels found in part-body irradi-
ated mice [12]. Whether these elevated levels of TGF-β
have a relationship to the extent and duration of prior ther-
apy remains to be determined.
Some studies [4], but not all [13], have not found an
association between poor BSC collection and marrow
metastases. The current study suggested that collection of
progenitors was less successful if marrow metastases were
detected. The apparent discrepancies in reported studies
might reﬂect the sensitivity of the methods used to detect
marrow metastases. This study used relatively sensitive
immunocytochemical and immunohistochemical techniques
as well as standard histopathologic methods.
These observations suggest that an evaluation of the
prior therapy history of the patients and the metastatic or
micrometastatic status of their bone marrow should identify
those breast cancer patients more likely to require a greater
number of aphereses or an increased apheresis volume to
achieve an adequate BSC collection. This study also empha-
sizes that the mechanisms responsible for poor mobilization
are not entirely understood.
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